JANSSEN Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN, and when can generic versions of JANSSEN drugs launch?
JANSSEN has seventy-eight approved drugs.
There are seventy-six US patents protecting JANSSEN drugs.
There are two thousand two hundred and ten patent family members on JANSSEN drugs in seventy-two countries and four hundred and forty-three supplementary protection certificates in twenty countries.
Summary for JANSSEN
International Patents: | 2210 |
US Patents: | 76 |
Tradenames: | 74 |
Ingredients: | 51 |
NDAs: | 78 |
Patent Litigation for JANSSEN: | See patent lawsuits for JANSSEN |
PTAB Cases with JANSSEN as patent owner: | See PTAB cases with JANSSEN as patent owner |
Drugs and US Patents for JANSSEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | 11,684,620 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Janssen Pharms | LEVAQUIN | levofloxacin | TABLET;ORAL | 020634-001 | Dec 20, 1996 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Janssen Therap | SIRTURO | bedaquiline fumarate | TABLET;ORAL | 204384-002 | May 27, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-010 | Mar 18, 2021 | RX | Yes | No | 9,062,014 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JANSSEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen R And D | INTELENCE | etravirine | TABLET;ORAL | 022187-001 | Jan 18, 2008 | 7,887,845*PED | ⤷ Try a Trial |
Janssen R And D | INTELENCE | etravirine | TABLET;ORAL | 022187-003 | Mar 26, 2012 | 7,887,845*PED | ⤷ Try a Trial |
Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-001 | Jul 1, 2011 | 7,585,860 | ⤷ Try a Trial |
Janssen Pharms | RAZADYNE ER | galantamine hydrobromide | CAPSULE, EXTENDED RELEASE;ORAL | 021615-003 | Apr 1, 2005 | 4,663,318 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Solution | 25 mg/mL | ➤ Subscribe | 2009-07-30 |
➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg | ➤ Subscribe | 2005-04-11 |
➤ Subscribe | Extended-release Injectable Suspension | 39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL | ➤ Subscribe | 2017-11-21 |
➤ Subscribe | Extended-release Tablets | 18 mg*, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
➤ Subscribe | Tablets | 500 mg | ➤ Subscribe | 2017-08-23 |
➤ Subscribe | Tablets | 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg | ➤ Subscribe | 2017-03-29 |
➤ Subscribe | Extended-release Capsules | 16 mg and 24 mg | ➤ Subscribe | 2006-03-11 |
➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2013-05-14 |
➤ Subscribe | Tablets | 25 mg, 100 mg and 200 mg | ➤ Subscribe | 2001-12-26 |
➤ Subscribe | Capsules | 15 mg and 25 mg | ➤ Subscribe | 2005-09-07 |
➤ Subscribe | Tablets | 10 mg, 15 mg, and 20 mg | ➤ Subscribe | 2015-07-01 |
➤ Subscribe | Tablets | 4 mg, 8 mg and 12 mg | ➤ Subscribe | 2005-02-28 |
➤ Subscribe | Orally Disintegrating Tablets | 3 mg and 4 mg | ➤ Subscribe | 2005-03-23 |
➤ Subscribe | Extended-release Tablets | 18 mg, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2015-04-28 |
➤ Subscribe | Tablets | 6.25 mg and 12.5 mg | ➤ Subscribe | 2005-12-08 |
➤ Subscribe | Extended-release Capsules | 8 mg | ➤ Subscribe | 2006-03-02 |
➤ Subscribe | Tablets | 100 mg and 300 mg | ➤ Subscribe | 2017-03-29 |
➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2013-05-03 |
➤ Subscribe | Tablets | 50 mg | ➤ Subscribe | 2005-09-08 |
➤ Subscribe | Transdermal System | 0.15 mg/0.02 mg per 24 hours | ➤ Subscribe | 2007-03-22 |
International Patents for JANSSEN Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Nicaragua | 201900009 | ⤷ Try a Trial |
Austria | 508748 | ⤷ Try a Trial |
New Zealand | 545305 | ⤷ Try a Trial |
China | 110198716 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for JANSSEN Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1453521 | 93156 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
1651658 | 14C0034 | France | ⤷ Try a Trial | PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131119 |
1633724 | C 2015 011 | Romania | ⤷ Try a Trial | PRODUCT NAME: OLAPARIB; NATIONAL AUTHORISATION NUMBER: EU/1/14/959/001; DATE OF NATIONAL AUTHORISATION: 20141216; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/959/001; DATE OF FIRST AUTHORISATION IN EEA: 20141216 |
1453521 | 122015000093 | Germany | ⤷ Try a Trial | PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.